Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...
Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...
Carbonated drinks known as sparkling, fizzy, seltzer and soda waters are thought to impact the waistline. A new study weighs ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
Don't expect to shed pounds solely due to your choice of beverage. The benefits of drinking carbonated water for weight loss ...
The body absorbs the carbon in a way that “may support weight loss,” according to a new study, but carbonated drinks are not ...
The diabetes startup is prescribing GLP-1 drugs for weight loss to help employers manage costs. Its CEO says it's nearing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback